915 abstracts found.



Results filter

Development of potent water-soluble inhibitors of the DNA-dependent protein kinase (DNA-PK)

Year:

Session type:

Celine Cano1, Nicola Curtin1, Bernard Golding1, Karen Haggerty1, Ian Hardcastle1, Marc Hummersone2, Keith Menear2, Caroline Richardson2, Graeme Smith2, Roger Griffin1

1Northern Institute for Cancer Research, Newcastle Upon Tyne, UK, 2KuDOS Pharmaceuticals Ltd, Cambridge, UK


Using patient involvement and patient experience to drive service change: a case example from cancer care

Year:

Session type:

Liz Forbat, Kate Knighting, Sandi Cayless, Nora Kearney

Cancer Care Research Centre, Stirling, UK


From stem cells to cancer: deciphering the Mitf code

Year:

Session type:

Colin Goding

Ludwig Institute for Cancer Research, Oxford, UK


Molecular biology of hepatocellular carcinoma

Year:

Session type:

Nathalie Wong

Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China


Increasing public awareness in research from the perspective of a cancer care and support charity

Year:

Session type:

Jim Elliott

Macmillan Cancer Support, UK


Melanoma stem cells: implications for therapy

Year:

Session type:

Markus Frank

Brigham and Women’s Hospital, Boston, USA


The role of ablative therapies in hepatocellular carcinoma

Year:

Session type:

Riccardo Lencioni

University of Pisa, Rome, Italy


Personal experiences of clinical trials – a new website resource

Year:

Session type:

Louise Locock

DIPEx, University of Oxford, UK


Harnessing NKT cells in cancer vaccination strategies

Year:

Session type:

Vincenzo Cerundolo

University of Oxford, UK


New systemic approaches and trial design

Year:

Session type:

Philip Johnson

University of Birmingham, UK


Increasing public awareness of clinical trials- a research nurse perspective

Year:

Session type:

Barbara Moore

Wales Cancer Trials Network, Cardiff, UK


Chemical-genetic approaches to identify novel compounds that sensitize melanocytes for cell death

Year:

Session type:

Hironori Ishizaki, Michaela Spitzer, Jan Wildenhain, Ian Jackson, Mike Tyers, Elizabeth Patton

University of Edinburgh, UK


Current and future trials in hepatocellular cancer

Year:

Session type:

Tim Meyer

Royal Free Hospital, London, UK


Personalizing in silico models of tumours with in vivo medical images

Year:

Session type:

Nicholas Ayache

INRIA (French Research Institute of Computer Science and Automatic Control), Sophia-Antipolis, France


Defining who benefits from treatment for melanoma

Year:

Session type:

Mark Middleton

University of Oxford, UK


IMP321 and weekly paclitaxel as first-line chemo-immunotherapy in metastatic breast cancer (MBC)

Year:

Session type:

Frédéric Triebel

Immutep SA, Paris, France


Emerging architecture of colorectal cancer predisposition

Year:

Session type:

Richard Houlston

The Institute of Cancer Research, Sutton, UK


Role of PI3K signalling pathway in modulating hypoxia response in neuroblastoma

Year:

Session type:

Esther Bridges, Malin Åkerblom, Siv Beckman, Sven Påhlman

Lund University, Malmö, Sweden, Sweden


Use of nanomagnets to enhance monocyte delivery of gene therapy to tumours

Year:

Session type:

Munitta Muthana1, Simon Scott2, Craig Murdoch1, Neil Farrow3, Jon Dobson3, Claire Lewis1

1University of Sheffield, Sheffield, UK, 2University of Kent, Kent, UK, 3Keele University School of Medicine, Stoke on Trent, UK


Targeting the Wnt signalling pathway

Year:

Session type:

Trevor Dale

Cardiff University, UK


Improving ethnic data collection for cancer

Year:

Session type:

Janet Dunn

Warwick Medical School, University of Warwick, UK


Should we select specific chemotherapy regimens based on tumour molecular subtypes?

Year:

Session type:

Herve Bonnefoi

Hospitaux Universitaires de Geneve, Geneva, Switzerland


Immunological targeting of the cancer phosphoproteome

Year:

Session type:

Mark Cobbold2, Andrew Norris4, Fiyas Mohammed1, Joy M. Polefrome4, Jie Qian4, Andrea M. De Santis4, Angela L. Zarling3, Jefferey Shabanowitz4, Benjamin E. Willcox1, Michael E. Williams5, Donald F. Hunt4, Victor H. Engelhard3

1CR-UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK, 2Department of Clinical Immunology, University of Birmingham, Birmingham, UK, 3Beirne Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA, 4Department of Chemistry, University of Virginia, Charlottesville, VA, USA, 5Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA


Predicting response to epidermal growth factor receptor inhibitors in colorectal cancer

Year:

Session type:

Sabine Tejpar

University Hospital Gasthuisberg, Leuven, Belgium


Title to be confirmed

Year:

Session type:

Tariq White

University of Leeds, UK


Title to be confirmed Laura van t’Veer The Netherlands Cancer Institute, Amsterdam, The Netherlands Abstract not received

Year:

Session type:


Targeting inflammatory cytokines using adenoviruses- gene delivery of biological therapies in ovarian cancer

Year:

Session type:

Michael Salako1, Hagen Kulbe1, Iain McNeish2, Frances Balkwill1

1Institute of Cancer and CR-UK Clinical Centre, Centre for Cancer and Inflammation, Barts and The London School of Medicine and Dentistry, London, UK, 2Institute of Cancer and CR-UK Clinical Centre, Centre for Molecular Oncology and Imaging, Barts and The London School of Medicine and Dentistry, London, UK


Pharmacogenetics in colorectal cancer therapy

Year:

Session type:

Howard McLeod

Washington University, St Louis, USA


Involvement of ethnic minorities in cancer research: experiences, barriers and recommendations

Year:

Session type:

Claire Foster

University of Southampton, UK


Triple Negative breast cancer: Diagnosis or dustbin?

Year:

Session type:

Andrew Tutt

Guy’s & St Thomas’s NHS Foundation Trust, London, UK


Title to be confirmed

Year:

Session type:

Michael Hengartner

Institute of Molecular Biology, University of Zurich, Switzerland


Investigating prognostic and predictive influences of germline polymorphisms on colorectal adenoma recurrence

Year:

Session type:

Richard Hubner1, Kenneth Muir2, Jo-Fen Liu2, Richard Logan2, Richard Houlston1

1Insititute of Cancer Research, Surrey, UK, 2University of Nottingham Medical School, Nottingham, UK


Geminin regulates DNA replication and predicts clinical outcome in breast cancer

Year:

Session type:

Mike Gonzalez

MRC Cancer Cell Unit, Cambridge, UK


ASPP2 mediates senescence and inhibits autophagy and tumourgenicity induced by H-RasV12

Year:

Session type:

Xin Lu

Ludwig Institute for Cancer Research, University of Oxford, UK


‘Better off dead’: thoughts of death and suicide in cancer patients

Year:

Session type:

Jane Walker

University of Edinburgh, UK


Integration of HER-2 result into breast multi-disciplinary decision making: results of a UK audit

Year:

Session type:

Louise Li, Mark Verrill

Northern Centre for Cancer Treatment, Newcastle Upon Tyne, UK


Role of autophagy in cancer progression and therapy

Year:

Session type:

Eileen White

Center for Advanced Biotechnology and Medicine, Piscataway, USA


Suicide rates in US cancer patients

Year:

Session type:

Stephanie Misono1,2, Noel S Weiss2,3, Jesse R Fann2,3, Mary Redman3, Bevan Yueh1, 2,3

1VA Puget Sound Health Care System, Seattle, USA, 2University of Washington, Seattle, USA, 3Fred Hutchinson Cancer Research Center, Seattle, USA


MR Imaging in breast cancer – results of the COMICE trial

Year:

Session type:

Lindsay Turnbull2, Ian Harvey2, Sarah Brown1, Andy Hanby3, Phil Drew4, Catherine Olivier1, Vicky Napp1, Julia Brown1

1Clinical Trials Research Unit, University of Leeds, Leeds, UK, 2Centre for MR Investigations, Hull Royal Infirmary, Hull, UK, 3St James's University Hospital, Leeds, UK, 4University of Hull, Hull, UK


Increasing melanoma cell death using an inhibitor of protein disulphide isomerases to abrogate stress-survival responses

Year:

Session type:

Penny Lovat1, Marco Corazzari2, Jane Armstrong1, Shaun Martin1, Vittoria Pagliarini2, David Hill1, Anna Brown1, Mauro Piacentini2, Mark Birch-Machin1, Chris Redfern1

1Newcastle University, Newcastle upon Tyne, UK, 2L’Spallanzani National Institute for Infectious Disease, Rome, Italy


The experiential landscape of terminal illness

Year:

Session type:

Harvey Chochinov

University of Manitoba and Manitoba Palliative Care Research Unit, Canada


Non standard management of older women with breast cancer in the UK

Year:

Session type:

Katrina Lavelle1, C Todd1, A Moran2, A Howell3, N Bundred4, M Campbell1

1School of Nursing, Midwifery and Social Work, University of Manchester, 2NorthWest Cancer Intelligence Service (NWCIS), UK, 3Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK, 4South Manchester University Hospitals NHS Trust, Withington Hospital, Manchester, UK


Role for autophagy in the establishment of senescence

Year:

Session type:

Andrew Young, Masako Narita, Manuela Ferreira, Kristina Kirschner, Fiona Watt, Masashi Narita

Cancer Research UK, Cambridge, UK


Continuity of care in patients with cancer: development and evaluation of a complex intervention

Year:

Session type:

Michael King1, Louise Jones2, Irwin Nazareth3, Alison Richardson4, Adrian Tookman2, Ona McCarthy1, Mary Rogers1

1University College London, London, UK, 2Marie Curie Palliative Care Research Unit, University College, London, London, UK, 3MRC General Practice Research Framework, London, UK, 4Department Cancer and Palliative Care Nursing, Kings College London, London, UK


Surgical mistreatment of older cancer patients

Year:

Session type:

Riccardo A. Audisio

Whiston Hospital, UK, and University of Liverpool, UK


The BH3 peptidomimetic obatoclax restores absent mitochondrial death signals in cisplatin resistant non-small cell lung cancer

Year:

Session type:

Nyree Crawford, Alex Chacko, Keenan Savage, Patrick Johnston, Dean Fennell

Queen's University Belfast, Northern Ireland, UK


Implementing and evaluating a four tier model of psychological support. Results from a three year study

Year:

Session type:

Kate Jenkins, Beccy Alberry, Sarah Pestell, Vivien North, Nigel North

Salisbury NHS Foundation Trust, Salisbury, UK


Anticancer treatment: what do older patients want?

Year:

Session type:

Martine Extermann

Moffitt Cancer Center, University of South Florida, Tampa, USA


Frequent somatic mutations of GNAQ in uveal melanoma and intradermal melanocytic proliferations

Year:

Session type:

Boris Bastian

University of California, San Francisco, USA


A systematic review of the information needs of partners and family members of cancer patients

Year:

Session type:

Eike Adams, Eila Watson, Mary Boulton

Oxford Brookes University, Oxford, UK